Electromed, Inc. (ELMD) presents a straightforward liquidation posture for a small-cap medical device company: positive equity recovery supported primarily by a large, current accounts receivable balance and minimal financial debt, with the asset base dominated by working capital rather than fixed or intangible assets. As of March 31, 2026, total stockholders' equity was $49.2M versus $45.4M at December 31, 2025, driven by $3.0M net income in Q3 FY2026 partially offset by $151K in share repurchases during the quarter. The September 2025 repurchase authorization has consumed $3.9M through period end, with $6.1M remaining under the $10M program. Accounts receivable net of allowances stood at $28.3M as of March 31, 2026, up from $24.7M at June 30, 2025, representing the largest single asset and the primary driver of liquidation recovery. At a 90-95% haircut, AR contributes approximately $25-27M to liquidation value. Inventory of $3.3M (net of $329K obsolescence reserve) applies a 60% haircut, yielding roughly $2.0M. PP&E and other long-lived assets (capitalized software $1.1M, ROU assets $146K) are immaterial at liquidation-adjusted values and would recover near zero under the intangibles haircut. The company carries no funded debt; the $10M BMO Bank N.A. revolving credit facility (entered December 2025, maturing December 2026) had a zero outstanding balance as of March 31, 2026. The credit facility carries a first-priority lien on substantially all assets, which is structurally senior to equity in any wind-down scenario but is currently undrawn and thus does not impair recovery. Liabilities are composed of operating accruals: warranty reserve $1.8M (up from $1.6M at June 30, 2025), accrued insurance recoupments $850K (up from $602K), accrued compensation, operating lease obligations (ROU liability declining, $146K asset suggests near-term expiry), and other current liabilities. No pension, no long-term debt, no goodwill, no acquired intangibles. The MFFAIS-reported OLV of $34.1M against a book equity of $49.2M reflects the expected haircut asymmetry: AR recovery below par, inventory at 60%, and full face-value recognition of liabilities. The filing discusses the One Big Beautiful Bill Act (OBBBA) enacted July 4, 2025, with an estimated $428K cash tax reduction in 2026 from accelerated R&D deduction elections; this is disclosed in MD&A but the associated deferred tax asset or payable movement is not separately tagged in XBRL in this filing. The accrued insurance recoupments line (elmd:AccruedInsuranceRecoupments) increased 41% QoQ from $602K to $850K and is worth monitoring as it represents third-party payer clawback exposure that sits at face value on wind-down.
▼ Community Notes